Escalon Richtung Norden - 500 Beiträge pro Seite

[tasmandevil]

Geringe MK 47,9 Mio.
5,0 Mio. Shares
Hohes Volumen ca. 500.000

WAYNE, Pa., Nov. 23 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced results for its fiscal first quarter ended September 30, 2004. For the first quarter of fiscal 2005, Escalon Medical reported net revenue of $5,292,161 compared to $3,411,642 in the prior year period, a 55.1% gain. Product revenue increased by 63.2% during the quarter to $4,636,457 from $2,841,127 in the prior year period attributable to the July 2004 acquisition of Drew Scientific Group, Plc. However, net income in the first quarter was $115,899, or $0.019 per diluted share, compared to net income of $623,156, or $0.154 per diluted share, in the first quarter of fiscal 2004, which included a $304,000 net loss attributable to Drew. Diluted shares outstanding increased by 52% quarter over quarter due to the issuance of 841,686 shares of an eventual 900,000 shares expected to be issued in connection with the acquisition of Drew, 800,000 common shares in the March 2004 private equity financing and the exercise of stock options. For the first quarter, Drew had revenue of $1,904,000. Excluding the impact of the acquisition, however, product sales were down 3.8%. Sonomed revenue decreased 3.6% to $1,644,000 compared to $1,705,000 in the prior year period. Sales of the Company`s pachymeter, after strong sales in the year ago period, declined, partially offset by increased sales of the new E-Z Scan(TM). Revenue in the Vascular business declined 5.3% to $695,000 in the first quarter of fiscal 2005 compared to $734,000 in the year ago period. The decline was related to lower stocking orders. Product revenue in the Company`s Medical / Trek / EMI business unit decreased 2.2% to $393,000 in the quarter from $402,000 in the first quarter of fiscal 2005. Other revenue increased 14.9% to $656,000 in the quarter compared to $571,000 in the year ago period. The increase relates to an increase in royalty payments from Intralase under a license of our intellectual properties. Partially offsetting the increase in other revenue was a decline in royalty revenue related to annual step-downs in the Company`s contract for Silicone Oil with Bausch & Lomb. Receipt of royalty revenue from future sales of Silicone Oil is expected to continue through contract termination in August 2005. The gross margin as a percent of product revenue was 42.4% in the current quarter compared to 57.3% in the year ago period primarily due to the operations of Drew. Excluding the impact of the acquisition, gross margin was 48.0%. Negatively impacting the gross margin in the quarter was product mix, including lower pachymeter sales and increased international sales at Sonomed. Marketing, general and administrative expenses were 40.6% of net revenues in the first quarter compared to 35.6% of net revenues in the year ago period and included additional expenses related to the operations of Drew. Research and development spending was $315,762 in the quarter compared to $207,130 in the year ago quarter, also related to the acquisition. "Escalon Medical has truly been transformed in our first quarter of fiscal 2005," commented Richard J. DePiano, Chairman and Chief Executive Officer. "In July we added an important third leg to our business portfolio with the acquisition of approximately 94% of the outstanding shares of Drew Scientific Group, Plc, a diagnostics company specializing in analytical systems for laboratory testing worldwide. The remaining outstanding Drew shares are expected to be acquired over the remainder of fiscal 2005. From a balance sheet standpoint, we also paid off all of the Escalon Medical term debt as well as our outstanding line of credit that existed prior to the acquisition, reducing total debt by $2.3 million. In addition, as of September 30, 2004, we have $5.9 million in cash, which puts us in a strong position to integrate the acquisition of Drew. Prior to acquisition, Drew`s ability to obtain raw materials and components was severely restricted due to prolonged liquidity constraints. These constraints were pervasive through all of Drew`s locations and affected all aspects of Drew`s operations. Escalon`s immediate operational priorities with respect to Drew have been to stabilize and increase Drew`s revenue base and to infuse Drew with working capital in the areas of manufacturing, sales and marketing and product development in order to remove the pre-acquisition liquidity constraints." "While revenue was soft at Sonomed, with sales of our pachymeter down after strong demand last year, we were pleased with the increased sales of our new B-Scan, the E-Z Scan(TM). We remain committed to enhancing our products through targeted research and development and to expanding our markets beyond the U.S. In our Vascular segment, revenue was primarily impacted by changes within our distribution channel, including providing relief from minimum purchase requirements to several of our distributors." "Looking ahead to the remainder of fiscal 2005, we are focused on integrating Drew. While Drew lost money in the quarter, we have been pleasantly surprised with our progress towards stabilizing the revenue base, and we are currently investing in its products to support growth and reduce costs where possible," concluded Mr. DePiano. Founded in 1987, Escalon develops, markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew, which operates as a separate division, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company`s distribution capabilities. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.

tasmandevil

[tasmandevil]

war wohl doch eher Süden

Aber nun geht`s Richtung 10 $

[tasmandevil]

Keiner an Escalon interessiert

Escalon Medical Corp. (ESMC) Reports Second Quarter Fiscal 2005 Results

WAYNE, Pa., Feb. 14 /PRNewswire-FirstCall/ -- Escalon Medical Corp. today announced results for its fiscal second quarter and six months ended December 31, 2004. For the second quarter of fiscal 2005, Escalon reported net revenue of $6,338,144 compared to $3,757,925 in the prior year period, a 68.7% gain. For the six month period ended December 31, 2004, Escalon reported net revenue of $11,639,801 compared to $7,169,567 in the prior period, a 62.4% gain. The Company, however, reported a net loss of $422,625, or $0.072 per diluted share, compared with net income of $820,961, or $0.196 per diluted share, in the second quarter of fiscal 2004. For the six month period ended December 31, 2004, the Company reported a net loss of $309,156, or $0.054 per diluted share, compared with net income of $1,444,117, or $0.357 per diluted share in the prior year. The increase in net revenue as well as the reduction in profitability was primarily attributable to the July 2004 acquisition of Drew Scientific, Plc ("Drew"). Diluted shares outstanding increased by 40.2% quarter over quarter and 41.3% year over year due to the issuance of 841,686 of a potential 900,000 shares related to the acquisition of Drew, 800,000 common shares in the March 2004 private equity financing and the exercise of stock options.

(See Story from BioSpace.com) (2/15/05)


Steigende Umsätze - steigender Gewinn

Ergebnis wurde durch die Übernahme von Drew Scient. negativ beeinflußt.

Absolute Kaufgelegenheit

tasmandevil

[tasmandevil]

Was sag ich denn